Preferred Stock Channel
Quotes delayed 20 minutes


Strong Buy (4.00 out of 4)
95th percentile
(ranked higher than approx. 95% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com
www.valueforum.com/7/
Free Preferred Stock Newsletter
Gain access to weekly reports with featured preferred stock screens, new preferred stock offerings, and more.

Slideshow Preferred Stock Offerings

By Preferred Stock Channel Staff, updated Saturday, July 4, 10:43 PM

Slide #365. Dynavax Technologies Corporation Preferred Stock Offering

Company: Dynavax Technologies Corporation (NASDAQ:DVAX)
Date announced: 10/24/2013
Shares Offered: 43,430
Date of Pricing: 10/25/2013
Price Per Share: $1,075.00
Preferred Stock Offering Details: Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it intends to concurrently offer to sell, subject to market and other conditions: (i) shares of its common stock in an underwritten public offering, and (ii) shares of its Series B Convertible Preferred Stock ("Series B") in a separate underwritten public offering. The Series B is non-voting and convertible into shares of Dynavax common stock, provided that conversion will be prohibited if, as a result, the holder and its affiliates would own more than 9.98% of the total number of shares of Dynavax common stock then outstanding. Dynavax anticipates using the net proceeds from the offerings primarily to fund development activities predominantly associated with conducting an additional Phase 3 study of HEPLISAV and seeking regulatory approval to commercialize the vaccine in the United States and Europe, and for other general corporate purposes, including working capital.

Dynavax Technologies is a biopharmaceutical company focused on utilizing the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Co.'s commercial product, HEPLISAV-B® (Hepatitis B Vaccine (Recombinant), Adjuvanted), is approved for prevention of infection caused by various known subtypes of hepatitis B virus in adults age 18 years and older. Co.'s development efforts are focused on stimulating the innate immune response to treat cancer in combination with other immunomodulatory agents. Co.'s pipeline of product candidates includes: SD-101, which is its cancer immunotherapy candidate; and DV281, which is an investigational TLR9 agonist.
Open the DVAX Page at Preferred Stock Channel »

Name:  Dynavax Technologies Corp
Website:  www.dynavax.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding DVAX:  19 (see which ones)
Total Market Value Held by ETFs:  $90,484,237
Total Market Capitalization:  $766,000,000
% of Market Cap. Held by ETFs:  11.81%
 

Open the DVAX Page at Preferred Stock Channel (in a new window) »

Top Ten Highest Yielding Preferred Stocks
Feel-Good Income: Socially Responsible Preferreds
Dividend Channel's 25 S.A.F.E. Dividend Stocks
Increasing Payments For Decades

Safer than S.A.F.E: Preferreds of Dividend Channel's
S.A.F.E. Dividend Stocks

Recent Preferred Stock Offerings
Preferred Stocks of Dow Components
Preferred Stocks of S&P 500 Components
Preferred Stocks By Industry
Preferred Stocks Where Insiders Are Buying The Common
High Yield Preferred Stocks
Preferreds Trading At Premiums To Liquidation Preference
Preferreds Trading At Discounts To Liquidation Preference
The Top 10 DividendRank'ed U.S. Stocks
The Top 10 DividendRank'ed Canadian Stocks
Top 25 Broker Analyst Picks of the S&P 500
Stock market game

Preferred Stock Offerings - Slide 365 of 504 | www.PreferredStockChannel.com | Copyright © 2011 - 2020, All Rights Reserved

Nothing in Preferred Stock Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and dividend videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact Preferred Stock Channel; Meet Our Editorial Staff.